GlassScriptPhysician profile
Kyle L Snell
NPI 1215297973
$1,856.45
in general payments reported to CMS, 2019-2025
15 companies · $50.70 in 2025
The $50.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $32.20 · 2021: $15.15 · 2022: $214 · 2023: $791 · 2024: $222 · 2025: $50.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $333.71 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $307.71 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bioventus LLC | $253.90 | 2019-2025 | Durolane, Durolane |
| Pfizer INC. | $180.03 | 2022-2024 | |
| Abbvie INC. | $175.77 | 2022-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.58 | 2019-2024 | Ofev |
| Ironshore Pharmaceuticals INC. | $131.53 | 2019 | |
| Lilly USA, LLC | $96.91 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $76.40 | 2023-2024 | Farxiga |
| Ferring Pharmaceuticals INC. | $52.08 | 2022-2024 | Euflexxa |
| Sanofi-Aventis U.S. LLC | $22.49 | 2022 | |
| Dexcom, INC. | $18.96 | 2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $16.06 | 2023 | Tlando, Xyosted, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $15.82 | 2020 | |
| Philips North America LLC | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.